Join
Live feed
·
PRReleasevia Quantisnow
Kaleido Biosciences Inc. logo

Kaleido Biosciences Announces New Clinical and Preclinical Data Supporting Advancement of KB295 to a Phase 2 Clinical Study in Mild-to-Moderate Ulcerative Colitis

ByQuantisnow·Wall Street's wire, on your screen.
KLDO· Kaleido Biosciences Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track KLDO (Kaleido Biosciences Inc.) and more on Quantisnow.